S
Sunil K. Upadhyay
Researcher at University of Michigan
Publications - 23
Citations - 838
Sunil K. Upadhyay is an academic researcher from University of Michigan. The author has contributed to research in topics: Prostate cancer & Androgen receptor. The author has an hindex of 12, co-authored 23 publications receiving 698 citations. Previous affiliations of Sunil K. Upadhyay include University of New Orleans.
Papers
More filters
Journal ArticleDOI
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Zhenfei Li,Andrew C. Bishop,Mohammad Alyamani,Jorge A. Garcia,Robert Dreicer,Dustin R. Bunch,JJ Liu,Sunil K. Upadhyay,Richard J. Auchus,Nima Sharifi +9 more
TL;DR: It is proposed that direct treatment with D4A would be more clinically effective than abiraterone treatment, because competitive androgen receptor antagonism by D2A is comparable to the potent antagonist enzalutamide and D3A also has more potent anti-tumour activity against xenograft tumours than abIRaterone.
Journal ArticleDOI
Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency
Adina F. Turcu,Aya T Nanba,Robert Chomic,Sunil K. Upadhyay,Thomas J. Giordano,James J. Shields,Deborah P. Merke,William E. Rainey,Richard J. Auchus +8 more
TL;DR: The data suggest that 11oxC19 steroids are specific biomarkers of adrenal-derived androgen excess, and these steroids are elevated in both men and women with classic 21OHD.
Journal ArticleDOI
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
Zhenfei Li,Mohammad Alyamani,Jianneng Li,Kevin Rogacki,Mohamad E. Abazeed,Sunil K. Upadhyay,Steven P. Balk,Mary-Ellen Taplin,Richard J. Auchus,Nima Sharifi +9 more
TL;DR: The findings suggest a previously unappreciated and biochemically specific method of clinically fine-tuning abiraterone metabolism to optimize therapy, and demonstrate the specific biochemical effects of pharmacological 5α-reductase inhibition on abiraters metabolism.
Journal ArticleDOI
High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein–Protein Interaction
Shihan He,Timothy J. Senter,Jonathan Pollock,Changho Han,Sunil K. Upadhyay,Trupta Purohit,Rocco D. Gogliotti,Craig W. Lindsley,Tomasz Cierpicki,Shaun R. Stauffer,Jolanta Grembecka +10 more
TL;DR: Development of a novel class of small-molecule inhibitors of the menin–MLL interaction, the hydroxy- and aminomethylpiperidine compounds, which originated from HTS of ∼288000 small molecules are reported.
Journal ArticleDOI
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer
Mohammad Alyamani,Hamid Emamekhoo,Sunho Park,Jennifer Taylor,Nima Almassi,Sunil K. Upadhyay,Allison Janine Tyler,Michael P. Berk,Bo Hu,Tae Hyun Hwang,William D. Figg,Cody J. Peer,Caly Chien,Vadim S. Koshkin,Prateek Mendiratta,Petros Grivas,Brian I. Rini,Jorge A. Garcia,Richard J. Auchus,Nima Sharifi +19 more
TL;DR: Increased generation of 3-keto-5&agr;-abiraterone in patients with HSD3B1(1245C) might partially negate abirater one benefits in these patients who are otherwise more likely to benefit from CYP17A1 inhibition.